Exclusive

Publication

Byline

Obesity drugs may spur licensing, distribution deals for Indian drugmakers after patent expires

New Delhi, Jan. 2 -- The growing popularity of obesity drugs is expected to spur Indian pharma companies to sign licensing partnerships and distribution deals as they eye the lucrative segment. Indian... Read More


Cipla ties up with Pfizer for exclusive marketing of four brands

New Delhi, Dec. 19 -- Pfizer India and Cipla announced a partnership on Friday in which Cipla will exclusively market and distribute four Pfizer brands in India to increase their reach. These include... Read More


Concentric scale-ups: Mid-tier hospitals make expansion bets as large rivals consolidate

New Delhi, Dec. 16 -- Even as large hospitals in India rapidly consolidate, smaller corporate chains are aggressively expanding with an aim to grow into regional leaders - which, experts say, in turn,... Read More


Novo Nordisk launches Ozempic at Rs.2.2k a wk

MUMBAI, Dec. 13 -- Danish drugmaker Novo Nordisk on Friday launched its blockbuster diabetes drug Ozempic in India, with a starting price of Rs.2,200 per week. For a four-week course, the entry 0.25 m... Read More


Novo Nordisk launches Ozempic, at Rs.2.2k a week

MUMBAI, Dec. 13 -- Danish drugmaker Novo Nordisk on Friday launched its blockbuster diabetes drug Ozempic in India, with a starting price of Rs.2,200 per week. For a four-week course, the entry 0.25 m... Read More


Ozempic an "epic launch" in India: Novo Nordisk India MD Vikrant Shrotriya

MUMBAI, Dec. 12 -- Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday, pricing the entry 0.25 mg dose at Rs.8,800 for a four-week course. The launch comes ... Read More


With a Rs.2,200-a-week price tag, Ozempic enters India as Novo Nordisk steps up its obesity bet

MUMBAI, Dec. 12 -- Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday, with a headline starting price of Rs.2,200 per week. For a four-week course, the ent... Read More


French drugmaker Servier firms up India focus with manufacturing tie-ups, trial plans

New Delhi, Dec. 10 -- French pharmaceutical group Servier is sharpening its India strategy with a string of new oncology launches focused on rare cancers, plans for local manufacturing of active ingre... Read More


Biocon to merge biologics unit in $5.5 billion deal

New Delhi, Dec. 6 -- Biocon Ltd will integrate Biocon Biologics Ltd as a wholly owned subsidiary in a deal valuing the unit at $5.5 billion, the company said on Saturday. Biocon will acquire the rema... Read More


Mint Explainer: Does India need special courts for complex drug patent wars?

Mumbai, Dec. 6 -- On 2 December, the Delhi high court allowed domestic drugmaker Dr Reddy's Laboratories Ltd to manufacture the blockbuster weight-loss injection semaglutide, for which global pharma g... Read More